白介素17与支气管哮喘气道炎症的研究进展

Research of IL-17 and airway inflammation in bronchial asthma

支气管哮喘（简称哮喘）是一种慢性呼吸道炎症性疾病，这种疾病在免疫病理学、临床表型、对治疗的反应、自然史方面存在异型却是越来越明显。曾经被视为纯粹的辅助性T细胞（Th）2型淋巴细胞、免疫球蛋白E、肥大细胞、嗜酸粒细胞、巨噬细胞和细胞因子主导的过敏性疾病，疾病还涉及局部上皮细胞、间质、血管、神经系统指挥的Th2细胞表型，以及通过异常损伤修复机制的气道壁重塑。近年发现IL-17在哮喘免疫过程起着重要作用，本文就哮喘气道炎症与IL-17研究进展综述如下。

Bronchial asthma （asthma） is a chronic airway inflammation disorder. It is becoming increasingly apparent that the disease is heterogeneous with respect to immunopathology, clinical phenotypes, response to therapies, and natural history. Once considered purely an allergic disorder dominated by Th2 type lymphocytes, IgE, mast cells, eosinophils, macrophages, and cytokines, the disease also involves local epithelial, mesenchymal, vascular and neurologic events that are involved in directing the Th2 phenotype to the lung and through aberrant injury-repair mechanisms to remodeling of the airway wall. IL-17 is implicated in numerous immune and inflammatory responses primarily as a pro- inflammatory regulator by inducing the expression of various inflammatory mediators, such as cytokines, chemokines, adhesion molecules, and growth factors. IL-17 has been suggested as a crucial regulator of allergic asthma. In this review, we focus primarily on the regulatory pathways and roles of IL-17 in airway inflammation and scrutinize the therapeutic potential of various strategies targeting IL 17 for asthma.